182 related articles for article (PubMed ID: 6626318)
1. [Possible applications of living BCG and the BCG cell wall in immunotherapy].
Canti GF; Franco P; Ricci L
Boll Ist Sieroter Milan; 1983 May; 62(2):125-9. PubMed ID: 6626318
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of immunologic tumor regression by intratumoral administration of dendritic cells in combination with cryoablative tumor pretreatment and Bacillus Calmette-Guerin cell wall skeleton stimulation.
Udagawa M; Kudo-Saito C; Hasegawa G; Yano K; Yamamoto A; Yaguchi M; Toda M; Azuma I; Iwai T; Kawakami Y
Clin Cancer Res; 2006 Dec; 12(24):7465-75. PubMed ID: 17189420
[TBL] [Abstract][Full Text] [Related]
3. Immunoprotection against murine bladder carcinoma by octaarginine-modified liposomes incorporating cell wall of Mycobacterium bovis bacillus Calmette-Guérin.
Joraku A; Homhuan A; Kawai K; Yamamoto T; Miyazaki J; Kogure K; Yano I; Harashima H; Akaza H
BJU Int; 2009 Mar; 103(5):686-93. PubMed ID: 19040525
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy of established micrometastases with Bacillus Calmette-Guérin tumor cell vaccine.
Hanna MG; Peters LC
Cancer Res; 1978 Jan; 38(1):204-9. PubMed ID: 201374
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant-antigen requirements for active specific immunotherapy of microscopic metastases remaining after surgery.
Ashley MP; Zbar B; Hunter JT; Rapp HJ; Sugimoto T
Cancer Res; 1980 Nov; 40(11):4197-203. PubMed ID: 7471060
[TBL] [Abstract][Full Text] [Related]
6. Changes in mucosal immune cells of bladder tumor patient after BCG intravesical immunotherapy.
Chang SG; Lee SJ; Huh JS; Lee JH
Oncol Rep; 2001; 8(2):257-61. PubMed ID: 11182036
[TBL] [Abstract][Full Text] [Related]
7. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
[TBL] [Abstract][Full Text] [Related]
8. Genetically regulated response to intravesical bacillus Calmette Guerin immunotherapy of orthotopic murine bladder tumor.
Kadhim SA; Chin JL; Batislam E; Karlik SJ; Garcia B; Skamene E
J Urol; 1997 Aug; 158(2):646-52. PubMed ID: 9224385
[TBL] [Abstract][Full Text] [Related]
9. Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy.
Ayari C; LaRue H; Hovington H; Decobert M; Harel F; Bergeron A; Têtu B; Lacombe L; Fradet Y
Eur Urol; 2009 Jun; 55(6):1386-95. PubMed ID: 19193487
[TBL] [Abstract][Full Text] [Related]
10. [Antitumor activity of bacterial fractions and related synthetic compounds].
Azuma I; Yamamura Y
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2691-9. PubMed ID: 6508322
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy by intralesional injection of BCG cell walls or live BCG in bovine ocular squamous cell carcinoma: a preliminary report.
Klein WR; Ruitenberg EJ; Steerenberg PA; de Jong WH; Kruizinga W; Misdorp W; Bier J; Tiesjema RH; Kreeftenberg JG; Teppema JS; Rapp HJ
J Natl Cancer Inst; 1982 Nov; 69(5):1095-103. PubMed ID: 6957655
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of bacillus Calmette-Guérin-induced nitric oxide in bladder tumor cells may improve BCG treatment.
Alvarez V; Lodillinsky C; Umerez S; Sandes E; Eiján AM
Int J Mol Med; 2005 Oct; 16(4):565-71. PubMed ID: 16142388
[TBL] [Abstract][Full Text] [Related]
13. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
[TBL] [Abstract][Full Text] [Related]
14. [Cancer and BCG].
Rumi LS
Acta Physiol Lat Am; 1981; 31(1):25-34. PubMed ID: 7187581
[TBL] [Abstract][Full Text] [Related]
15. Mycobacterial cell wall extract for treatment of carcinoma in situ of the bladder.
Morales A; Chin JL; Ramsey EW
J Urol; 2001 Nov; 166(5):1633-7; discussion 1637-8. PubMed ID: 11586191
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of action of intravesical bacille Calmette-Guérin: local immune mechanisms.
Prescott S; Jackson AM; Hawkyard SJ; Alexandroff AB; James K
Clin Infect Dis; 2000 Sep; 31 Suppl 3():S91-3. PubMed ID: 11010831
[TBL] [Abstract][Full Text] [Related]
17. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity.
Mangsbo SM; Ninalga C; Essand M; Loskog A; Tötterman TH
J Immunother; 2008 Jan; 31(1):34-42. PubMed ID: 18157010
[TBL] [Abstract][Full Text] [Related]
18. Neutrophil granulocytes are required for effective Bacillus Calmette-Guérin immunotherapy of bladder cancer and orchestrate local immune responses.
Suttmann H; Riemensberger J; Bentien G; Schmaltz D; Stöckle M; Jocham D; Böhle A; Brandau S
Cancer Res; 2006 Aug; 66(16):8250-7. PubMed ID: 16912205
[TBL] [Abstract][Full Text] [Related]
19. Eradication by active specific immunotherapy of established tumor transplants and microscopic lymph node metastases.
Yarkoni E; Ashley MP; Zbar B; Sugimoto T; Rapp HJ
Cancer Res; 1982 Jul; 42(7):2544-6. PubMed ID: 7083146
[TBL] [Abstract][Full Text] [Related]
20. Cytokine gene expression in a mouse model: the first instillations with viable bacillus Calmette-Guerin determine the succeeding Th1 response.
De Boer EC; Rooijakkers SJ; Schamhart DH; Kurth KH
J Urol; 2003 Nov; 170(5):2004-8. PubMed ID: 14532842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]